Search research articles
Contact Us
Filters
Showing results (151-160 of 227) with videos related to
Page
of 23
Sort By:
JAMA Dermatology
|
November 10, 2021
Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study
Camille Roux, Emilie Sbidian, Jean-David Bouaziz, et al.
American Journal of Clinical Dermatology
|
May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
Scientific Reports
|
December 10, 2019
Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Nicolas Berkani, Pascal Joly, Marie-Laure Golinski, et al.
American Journal of Clinical Dermatology
|
September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
Scientific Reports
|
March 7, 2019
B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Nicolas Berkani, Pascal Joly, Marie-Laure Golinski, et al.
Dermatology (Basel, Switzerland)
|
February 3, 2021
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq
Florence Assan, Florence Tubach, Hugo Arlegui, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 7, 2010
Remission of severe CD8(+) cytotoxic T cell skin infiltrative disease in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy
Emilie Sbidian, Maxime Battistella, Jacqueline Rivet, et al.
The British Journal of Dermatology
|
September 23, 2025
Ustekinumab as a potential therapeutic agent in bullous pemphigoid: a biologic and clinical proof-of-concept study
Vlada Koliadenko, Pascal Joly, Flora Lemaire, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 227) with videos related to
Sort By:
Page
of 23
JAMA Dermatology
|
November 10, 2021
Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study
Camille Roux, Emilie Sbidian, Jean-David Bouaziz, et al.
American Journal of Clinical Dermatology
|
May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
Scientific Reports
|
December 10, 2019
Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Nicolas Berkani, Pascal Joly, Marie-Laure Golinski, et al.
American Journal of Clinical Dermatology
|
September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
Scientific Reports
|
March 7, 2019
B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Nicolas Berkani, Pascal Joly, Marie-Laure Golinski, et al.
Dermatology (Basel, Switzerland)
|
February 3, 2021
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq
Florence Assan, Florence Tubach, Hugo Arlegui, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 7, 2010
Remission of severe CD8(+) cytotoxic T cell skin infiltrative disease in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy
Emilie Sbidian, Maxime Battistella, Jacqueline Rivet, et al.
The British Journal of Dermatology
|
September 23, 2025
Ustekinumab as a potential therapeutic agent in bullous pemphigoid: a biologic and clinical proof-of-concept study
Vlada Koliadenko, Pascal Joly, Flora Lemaire, et al.
Page
of 23